Conference Presentation, Panel, Roundtable
Superbugs: Slowing the Spread of Antibiotic-Resistant Bacteria
- Annual deaths from antibiotic resistance are projected to surge from 750,000 to 10 million by 2050, with uncontrolled resistance potentially causing $100 trillion in global productivity losses by that same year.
- Mitigating this toll necessitates fundamental shifts in medicine, agriculture, business, trade, and family living, while the US government action plan funded in 2016 targets detection, response, prevention, and discovery across these domains.
- Specific pathogens pose severe immediate threats, such as CRE infections which kill up to 50% of victims, with the KPC form spreading from a single state in 2001 to all US states, and Clostridium difficile becoming the most common healthcare-associated infection at nearly 500,000 cases annually.
- Bacterial evolution is expected to accelerate due to rapid growth cycles of 20 minutes and selection pressures, necessitating immediate prevention strategies while antibiotic use remains unavoidable due to the microbiome.
- Pharmaceutical investment in antimicrobials faces limited returns compared to chronic disease drugs, currently driving approximately 70% of inappropriate antibiotic use due to a lack of diagnostic tools.
- Rapid diagnostics are expected to determine viral status in 20 minutes and provide susceptibility results within an hour for confirmed bacterial infections, potentially reducing selection pressure and synergizing with new drug discovery.
- Regulatory and economic incentives, including the GAIN Act and pending congressional bills to decouple DRG payments, are anticipated to spur a resurgence in antimicrobial discovery and enable value-based pricing models.
- Clinical outcomes for routine procedures like ankle or hernia surgery are expected to be severely impacted by rising resistance, while post-operative infection rates in settings without prophylaxis could reach approximately one-third.
- Public health initiatives include a central registry for tracking patient transfers, establishing regional laboratory networks for molecular epidemiology, and promoting community-based approaches to identify resistance mechanisms.
- Long-term societal shifts are projected to see changing norms where patients question antibiotic necessity, and most colonized individuals with resistant Klebsiella are expected to clear the organisms within six months without re-exposure.
- Global cooperation is deemed essential for addressing the issue, with efforts underway to improve laboratory capacity worldwide and utilize data to target interventions in communities where troublesome bacteria circulate.